Clene Inc (CLNN)
NASDAQConsumer StaplesBiotechnologySnapshot 2026-09-04
$3.85-3.75%
Close 2026-09-04 · 1-day change
NASDAQConsumer StaplesBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CLNN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CLNN — earnings miss
Dated 2026-08-14
Results of Operations and Financial Condition. On August 14, 2026, Clene Inc. (the “Company”) issued a press release announcing its second quarter 2026 financial results and recent operating highlights for its quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Sectio…
Why it matters: The RESTORE-ALS trial is key to proving CNM-Au8 works. Updates may affect how investors feel.
Watch forClene announces the initiation of the RESTORE-ALS trial as planned in Q1 2027.
Also watch forClene delays the initiation of the RESTORE-ALS trial beyond Q1 2027.
Why it matters: If revenue growth speeds up, it could signal a positive shift in business. This would help counter the current weak performance.
Supportive ifRevenue growth is speeding up again. It is now over 4% compared to last year.
Worry ifRevenue growth continues to slow or stays below 4% year over year.
Why it matters: Earnings results will show financial health and progress before the NDA submission.
Watch forQ3 2026 earnings show better financial results than Q2 2026.
Also watch forQ3 2026 earnings show worse financial results than Q2 2026.
Why it matters: Starting the Phase 3 trial is critical for validating CNM-Au8's effectiveness in ALS. It is a major milestone.
Supportive ifClene officially announces the start of the Phase 3 trial for CNM-Au8 in Q1 2027.
Worry ifClene delays the start of the Phase 3 trial beyond Q1 2027.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$207 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $643 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,975 loss on $10,000 · 39.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Positive FDA feedback would support the viability of CNM-Au8 as a treatment for ALS. It could influence investor confidence.
Watch forThe FDA says the data in the NDA supports faster approval.
Also watch forThe FDA says the submitted data is not enough for NDA review.
Why it matters: Earnings results will show if Clene's financial health is improving. This impacts investor sentiment.
Watch forClene reports earnings that are better than expected for Q2 2026.
Also watch forClene reports earnings that are worse than expected for Q2 2026.
Why it matters: Improving cash flow shows better expense management. This is key for long-term viability.
Supportive ifClene reports cash flow improvements, reducing negative cash flow in Q2 2026.
Worry ifCash flow remains negative or worsens in Q2 2026.
Why it matters: Good survival data may help with the NDA submission. It could show the drug works for ALS patients.
Supportive ifNew data shows that patients treated with CNM-Au8 lived longer than those who were not.
Worry ifData shows that CNM-Au8 does not help patients live longer than other treatments.
Why it matters: Improving cash flow is crucial for Clene's financial health. It shows they are managing expenses better.
Supportive ifCash flow turns positive or shows significant improvement in Q2 2026.
Worry ifCash flow remains negative or worsens in Q2 2026.
Why it matters: Positive data on NfL could strengthen the NDA submission and support CNM-Au8's approval for ALS treatment.
Supportive ifNew data shows a big drop in NfL. This drop links to better survival in ALS patients treated with CNM-Au8.
Worry ifData shows no clear link between NfL drop and clinical benefits.
Why it matters: Keeping operating costs low is key for the company's financial health.
Watch forOperating costs are down a lot compared to earlier quarters.
Also watch forOperating costs go up or stay high without a good reason.
Why it matters: The NDA submission is a key step for CNM-Au8's approval in ALS. Success could lead to new treatment options for patients.
Supportive ifClene submits the NDA for CNM-Au8 under the accelerated approval pathway by the end of Q4 2026.
Worry ifThe NDA submission is delayed beyond Q4 2026.
Why it matters: Having enough cash is important for daily work and clinical trials. It shows good financial health.
Supportive ifClene confirms cash and cash equivalents will support operations through late Q4 2026.
Worry ifClene announces cash runway will not extend into Q4 2026.